Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
|Articles|March 10, 2014
Three Reasons to Integrate a CTMS and EMR
Author(s)Lisa Haddican
Integrating a CTMS and an EMR can provide many benefits for supporting the health care needs of patients.
Advertisement
A clinical trial management system (CTMS) and an electronic medical record (EMR) are specialized systems that deliver functionality to meet unique needs. While the use of both systems is essential, integration between a CTMS and EMR can provide significant benefits for supporting the health care needs of patients. Here are 3 reasons to integrate systems:
Patient Safety
If a patient is participating in a clinical trial and visits a hospital for an emergency health issue, it’s important for a physician to be informed that the patient is currently enrolled in a clinical trial. By integrating a CTMS and EMR, a CTMS can communicate information that then allows the patient to be flagged as a clinical research participant within the EMR.
Billing Compliance
With separate systems that require manual data entry, it can be difficult to communicate and correctly route charges. This can lead to errors in clinical research billing and, subsequently, lead to billing compliance issues. When systems are integrated, information (such as charge determinations) is automatically communicated from a CTMS to an EMR. This can greatly decrease an organization’s risk of noncompliance.
Data Accuracy & Operational Efficiency
Using separate systems often means that staff members have to enter information twice. This can be time consuming and lead to errors in transcription. By automating the communication of information, staff members spend less time entering information manually into each system. This ensures accuracy and consistency of data, while streamlining staff workflows.
CTMS and EMR integration can provide many benefits for both patients and staff, and increase the quality of health care as a whole. It’s important that organizations are aware of the opportunities for systems to integrate. The OnCore Enterprise Research system offers options for integrating with EMR systems. To learn more about these options, download, “Automating the Flow of Information with OnCore Integrations.”
Lisa Haddican,
Advertisement
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
What Needs to Happen Beyond the Clinical Trial Modernization Act
3
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
4
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
5